Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MyoKardia Inc. MYOK

Healthcare Biotechnology
"MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac... see more

Recent & Breaking News (NDAQ:MYOK)

MyoKardia Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of MyoKardia, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - MYOK

Business Wire October 5, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of MyoKardia, Inc. to Bristol Myers Squibb

Newsfile October 5, 2020

(MYOK) Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price?

PR Newswire October 5, 2020

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Business Wire October 5, 2020

MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

GlobeNewswire September 9, 2020

MyoKardia to Participate in September Investor Conferences

GlobeNewswire September 2, 2020

MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire August 29, 2020

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

GlobeNewswire August 11, 2020

Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

GlobeNewswire August 10, 2020

MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 5, 2020

MyoKardia Reports Second Quarter 2020 Financial Results

GlobeNewswire August 4, 2020

CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

GlobeNewswire August 3, 2020

MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

GlobeNewswire August 3, 2020

MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

GlobeNewswire July 28, 2020

MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire July 23, 2020

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

GlobeNewswire July 21, 2020

MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

GlobeNewswire July 6, 2020

MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC's HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

GlobeNewswire June 22, 2020

MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology's Virtual Heart Failure Association Discoveries

GlobeNewswire June 19, 2020

MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 16, 2020